MX2022007174A - Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina. - Google Patents

Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Info

Publication number
MX2022007174A
MX2022007174A MX2022007174A MX2022007174A MX2022007174A MX 2022007174 A MX2022007174 A MX 2022007174A MX 2022007174 A MX2022007174 A MX 2022007174A MX 2022007174 A MX2022007174 A MX 2022007174A MX 2022007174 A MX2022007174 A MX 2022007174A
Authority
MX
Mexico
Prior art keywords
sub
compounds
treatment
deficiency
rypsin
Prior art date
Application number
MX2022007174A
Other languages
English (en)
Inventor
David John Fox
Nigel Ramsden
James Andrew Huntington
James Michael Tomlinson
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of MX2022007174A publication Critical patent/MX2022007174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Abstract

La invención se refiere a compuestos de ácido carboxílico especificados de fórmula (1), y composiciones farmacéuticas que contienen los compuestos. Los compuestos pueden ser inductores de a1-antitripsina (A1AT), y pueden usarse en el tratamiento de una enfermedad o trastorno, tal como deficiencia de a1-antitripsina (A1AD o AATD).
MX2022007174A 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina. MX2022007174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918410.0A GB201918410D0 (en) 2019-12-13 2019-12-13 Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2020/053187 WO2021116703A1 (en) 2019-12-13 2020-12-11 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2022007174A true MX2022007174A (es) 2022-08-25

Family

ID=69186879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007174A MX2022007174A (es) 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Country Status (13)

Country Link
US (1) US20230089087A1 (es)
EP (1) EP4072671A1 (es)
JP (1) JP2023506196A (es)
KR (1) KR20220127826A (es)
CN (1) CN115003380B (es)
AU (1) AU2020401452A1 (es)
BR (1) BR112022011527A2 (es)
CA (1) CA3164297A1 (es)
GB (1) GB201918410D0 (es)
IL (1) IL293747A (es)
MX (1) MX2022007174A (es)
WO (1) WO2021116703A1 (es)
ZA (1) ZA202207493B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202108542D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011110852A1 (en) * 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2012097371A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
WO2018104220A1 (en) * 2016-12-09 2018-06-14 Boehringer Ingelheim International Gmbh Sulfonamides as inhibitors of the uptake of extracellular citrate
MX2020013853A (es) 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
MX2021003819A (es) 2018-10-05 2021-06-23 Vertex Pharma Moduladores de alfa-1 antitripsina.
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin

Also Published As

Publication number Publication date
CN115003380B (zh) 2024-04-02
EP4072671A1 (en) 2022-10-19
AU2020401452A1 (en) 2022-07-14
IL293747A (en) 2022-08-01
ZA202207493B (en) 2023-12-20
CA3164297A1 (en) 2021-06-17
GB201918410D0 (en) 2020-01-29
JP2023506196A (ja) 2023-02-15
CN115003380A (zh) 2022-09-02
KR20220127826A (ko) 2022-09-20
US20230089087A1 (en) 2023-03-23
WO2021116703A1 (en) 2021-06-17
BR112022011527A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
MX2021004431A (es) Procesos novedosos.
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
NZ708593A (en) Novel pyrazole derivative
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
DE69306545D1 (de) Tucaresol als Mittel zur Immunopotentierung
MXPA05011524A (es) Acidos carboxilicos sustituidos.
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MX2021000894A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
EA201001781A1 (ru) Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2022007219A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
CR20210460A (es) Compuestos útiles en la terapia del vih
EA202192925A1 (ru) Твердые формы ингибитора glyt1
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren